Zofran Lawsuit Parties Submit Agenda for Upcoming Federal Status Conference, Bernstein Liebhard LLP Reports
April 13, 2016 (PRLEAP.COM) Business NewsApril 14, 2016 - The federal multidistrict litigation involving hundreds of product liability claims filed over the alleged association between Zofran and birth defects is scheduled to convene its next monthly Status Conference on April 14, 2016. According to an agenda jointly submitted by the parties on April 12th, the Conference will address a number of issues, including a request by GlaxoSmithKline that plaintiffs be required to identify whether they were prescribed the name-brand medication or a generic version of Zofran. The Court will also discuss the plaintiffs' proposal to address this product identification as part of fact sheets. (In Re Zofran Products Liability Litigation – MDL 2657)
"Our Firm is currently investigating claims on behalf of families who believe their child's birth defect may have been related to pre-natal Zofran exposure in the first trimester of pregnancy. We look forward to tomorrow's conference, as the issues to be addressed could impact our client's cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate Zofran lawsuits on behalf of families whose children were allegedly born with a serious birth defect due to pre-natal exposure to this medication.
Zofran and Birth Defects
Zofran is an anti-nausea medication that has only been approved to treat post-operative surgery patients or those undergoing certain cancer treatments. It has never been cleared by the U.S. Food & Drug Administration (FDA) to treat pregnancy-related nausea and vomiting, and the agency currently classifies the medication in Pregnancy Category B. This classification indicates that Zofran's effects on a developing pregnancy have not been well studied. In 2012, GlaxoSmithKline agreed to pay $3 billion to resolve illegal marketing charges with the U.S. Department of Justice , including accusations that it had wrongly marketed Zofran as an off-label treatment for morning sickness
Court documents indicate that at least 238 Zofran birth defects lawsuits have been filed in the District of Massachusetts, where all such federal cases have been centralized for the purposes of coordinated pretrial proceedings. Plaintiffs accuse Glaxo of improperly marketing the medication as a safe and effective treatment for morning sickness without FDA approval. The lawsuits also cite a number of studies which suggest that Zofran increases the risk of birth defects when used by expectant mothers in the first trimester of pregnancy, and allege that Glaxo concealed information about this risk from patients, doctors and regulators.
Children who allegedly suffered serious birth defects due to their mother's use of Zofran during the first trimester of pregnancy may be entitled to compensation from GlaxoSmithKline. To find out more about available legal options, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP